Nab-Paclitaxel vs Paclitaxel in Esophageal Cancer Study
Summary
An observational study (NCT07549269) registered April 24, 2026, comparing nab-paclitaxel (albumin-bound paclitaxel) versus conventional paclitaxel as part of neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma (ESCC). The retrospective IPTW-adjusted analysis addresses a gap in evidence regarding the comparative efficacy of these two widely used taxane-based agents in this clinical context.
“However, there is currently no definitive evidence comparing the efficacy of these two agents in the context of neoadjuvant therapy for ESCC.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
A new observational study record was added to ClinicalTrials.gov documenting a retrospective analysis comparing nab-paclitaxel and paclitaxel in the neoadjuvant treatment setting for esophageal squamous cell carcinoma. The study addresses the absence of definitive evidence comparing these two taxane agents, which are the most commonly used taxanes in ESCC treatment.
Healthcare providers and clinical investigators involved in esophageal cancer research may find this study relevant for understanding comparative effectiveness evidence gaps in neoadjuvant taxane-based regimens. The findings may inform future clinical trial design and treatment protocol development for ESCC patients.
Archived snapshot
Apr 25, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted Analysis
Observational NCT07549269 Kind: OBSERVATIONAL Apr 24, 2026
Abstract
Taxane-based agents are widely used in the treatment of esophageal squamous cell carcinoma (ESCC). Among these, nab-paclitaxel (albumin-bound paclitaxel) and paclitaxel are the most commonly used. However, there is currently no definitive evidence comparing the efficacy of these two agents in the context of neoadjuvant therapy for ESCC.
Conditions: Esophageal Cancer
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.